X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (20033) 20033
Newsletter (274) 274
Magazine Article (130) 130
Newspaper Article (89) 89
Book Chapter (63) 63
Transcript (31) 31
Dissertation (16) 16
Publication (13) 13
Book / eBook (9) 9
Web Resource (5) 5
Conference Proceeding (3) 3
Reference (3) 3
Government Document (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (17075) 17075
warfarin (12094) 12094
warfarin - therapeutic use (9035) 9035
female (8919) 8919
anticoagulants - therapeutic use (8915) 8915
male (8893) 8893
aged (6954) 6954
middle aged (6222) 6222
anticoagulants (5390) 5390
atrial fibrillation (4043) 4043
adult (3842) 3842
anticoagulants - adverse effects (3826) 3826
stroke (3679) 3679
risk factors (3632) 3632
anticoagulants - administration & dosage (3269) 3269
atrial fibrillation - drug therapy (3187) 3187
warfarin - adverse effects (3141) 3141
aged, 80 and over (3083) 3083
cardiac & cardiovascular systems (3048) 3048
anticoagulation (2832) 2832
pharmacology & pharmacy (2812) 2812
treatment outcome (2798) 2798
warfarin - administration & dosage (2674) 2674
prevention (2618) 2618
hematology (2570) 2570
peripheral vascular disease (2527) 2527
international normalized ratio (2484) 2484
therapy (2464) 2464
atrial fibrillation - complications (2450) 2450
stroke - prevention & control (2439) 2439
risk (2418) 2418
medicine, general & internal (2406) 2406
thromboembolism (2346) 2346
administration, oral (2286) 2286
dabigatran (2167) 2167
management (2166) 2166
hemorrhage - chemically induced (2078) 2078
retrospective studies (2070) 2070
atrial-fibrillation (1822) 1822
thrombosis (1815) 1815
aspirin (1749) 1749
care and treatment (1683) 1683
rivaroxaban (1582) 1582
aspirin - therapeutic use (1544) 1544
drug therapy (1521) 1521
abridged index medicus (1489) 1489
thromboembolism - prevention & control (1471) 1471
stroke - etiology (1462) 1462
heparin - therapeutic use (1450) 1450
analysis (1431) 1431
time factors (1419) 1419
medicine & public health (1407) 1407
patients (1384) 1384
venous thromboembolism (1364) 1364
surgery (1348) 1348
cardiac arrhythmia (1321) 1321
mortality (1277) 1277
hemorrhage (1270) 1270
prospective studies (1229) 1229
research (1229) 1229
stroke prevention (1208) 1208
follow-up studies (1204) 1204
health aspects (1192) 1192
drug interactions (1176) 1176
platelet aggregation inhibitors - therapeutic use (1172) 1172
bleeding (1170) 1170
antithrombotic therapy (1130) 1130
dosage and administration (1129) 1129
risk assessment (1121) 1121
cardiology (1107) 1107
safety (1039) 1039
apixaban (1032) 1032
fibrinolytic agents - therapeutic use (1026) 1026
vitamin k - antagonists & inhibitors (945) 945
adolescent (929) 929
dose-response relationship, drug (928) 928
internal medicine (909) 909
oral anticoagulants (892) 892
oral anticoagulation (890) 890
drug therapy, combination (881) 881
risk-factors (879) 879
complications (864) 864
heparin (854) 854
animals (842) 842
incidence (820) 820
pharmacogenetics (816) 816
prothrombin time (816) 816
molecular-weight heparin (811) 811
blood coagulation - drug effects (807) 807
fibrillation (805) 805
usage (803) 803
clinical neurology (801) 801
cohort studies (792) 792
randomized controlled trials as topic (789) 789
pharmacokinetics (773) 773
medical research (763) 763
cardiovascular (756) 756
anticoagulants - pharmacology (753) 753
complications and side effects (741) 741
clinical trials (740) 740
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (19878) 19878
Japanese (235) 235
French (141) 141
Spanish (116) 116
German (113) 113
Russian (84) 84
Italian (48) 48
Chinese (46) 46
Portuguese (39) 39
Swedish (25) 25
Norwegian (18) 18
Finnish (17) 17
Danish (15) 15
Czech (14) 14
Polish (13) 13
Hungarian (12) 12
Turkish (12) 12
Hebrew (9) 9
Dutch (5) 5
Korean (4) 4
Croatian (3) 3
Afrikaans (2) 2
Persian (2) 2
Serbian (2) 2
Ukrainian (2) 2
Arabic (1) 1
Bosnian (1) 1
Icelandic (1) 1
Lithuanian (1) 1
Slovak (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


American Heart Journal, ISSN 0002-8703, 2014, Volume 168, Issue 5, pp. 611 - 621
.... Anticoagulation uses 1 of 4 choices: bivalirudin, unfractionated heparin, enoxaparin, and fondaparinux... 
Cardiovascular | WORKING GROUP | CARDIAC & CARDIOVASCULAR SYSTEMS | ANTITHROMBOTIC THERAPY | DOUBLE-BLIND | ASSOCIATION TASK-FORCE | EUROPEAN-SOCIETY | ELEVATION MYOCARDIAL-INFARCTION | CONSENSUS DOCUMENT | PLATELET REACTIVITY | ATRIAL-FIBRILLATION | UNFRACTIONATED HEPARIN | Recombinant Proteins - therapeutic use | Prasugrel Hydrochloride | Thiophenes - therapeutic use | Hirudins | Humans | Heparin - therapeutic use | Enoxaparin - therapeutic use | Tyrosine - analogs & derivatives | Receptors, Thrombin - antagonists & inhibitors | Warfarin - therapeutic use | Tyrosine - therapeutic use | Adenosine - therapeutic use | Aspirin - therapeutic use | Drug Therapy, Combination | Platelet Aggregation Inhibitors - therapeutic use | Purinergic P2Y Receptor Antagonists - therapeutic use | Pyridines - therapeutic use | Polysaccharides - therapeutic use | Anticoagulants - therapeutic use | Piperazines - therapeutic use | Adenosine Monophosphate - therapeutic use | Lactones - therapeutic use | Platelet Glycoprotein GPIIb-IIIa Complex - antagonists & inhibitors | Acute Coronary Syndrome - drug therapy | Adenosine - analogs & derivatives | Adenosine Monophosphate - analogs & derivatives | Peptide Fragments - therapeutic use | Peptides - therapeutic use | Aspirin | Glycosaminoglycans | Atrial fibrillation | Mortality | Thrombin | Anticoagulants (Medicine) | Health aspects | Drug approval | Coronary heart disease | Heart attacks | Acute coronary syndromes | Drug therapy | Clinical outcomes
Journal Article
Journal Article
Journal Article
Chest, ISSN 0012-3692, 03/2016, Volume 149, Issue 3, pp. 756 - 766
Journal Article
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 09/2008, Volume 359, Issue 12, pp. 1238 - 1251
In this large clinical trial, aspirin plus extended-release dipyridamole was found to have an efficacy similar to that of clopidogrel in the prevention of... 
ACTIVE CONTROLLED-TRIALS | HIGH-RISK PATIENTS | TICLOPIDINE | TRANSIENT ISCHEMIC ATTACK | DOUBLE-BLIND | PREVENTION | RANDOMIZED CONTROLLED-TRIAL | ARTERIAL ORIGIN ESPRIT | CEREBRAL-ISCHEMIA | UMCG Approved | NON-INFERIORITY TRIALS | ISSUES | MEDICINE, GENERAL & INTERNAL | PLACEBO | DESIGN | WARFARIN | REGIMENS | Myocardial Infarction - epidemiology | Benzoates - therapeutic use | Ticlopidine - therapeutic use | Humans | Middle Aged | Male | Risk | Secondary Prevention | Aspirin - administration & dosage | Vascular Diseases - mortality | Angiotensin-Converting Enzyme Inhibitors - therapeutic use | Aspirin - adverse effects | Platelet Aggregation Inhibitors - administration & dosage | Ticlopidine - adverse effects | Dipyridamole - adverse effects | Female | Stroke - epidemiology | Drug Therapy, Combination | Platelet Aggregation Inhibitors - therapeutic use | Dipyridamole - therapeutic use | Benzimidazoles - therapeutic use | Platelet Aggregation Inhibitors - adverse effects | Brain Ischemia - epidemiology | Stroke - prevention & control | Double-Blind Method | Kaplan-Meier Estimate | Proportional Hazards Models | Brain Ischemia - prevention & control | Factor Analysis, Statistical | Stroke - drug therapy | Ticlopidine - analogs & derivatives | Aged | Hemorrhage - chemically induced | Delayed-Action Preparations | Stroke (Disease) | Aspirin | Usage | Care and treatment | Dipyridamole | Clopidogrel | Health aspects | Stroke | Index Medicus | Abridged Index Medicus | Recurrence | Brain Ischemia | Benzimidazoles | Follow-Up Studies | Neurons and Cognition | Cognition | Hemorrhage | Drug Delivery Systems | Life Sciences | Angiotensin II Type 1 Receptor Blockers | Angiotensin-Converting Enzyme Inhibitors | Vascular Diseases | Mental Status Schedule | Retrospective Studies | Severity of Illness Index | Disability Evaluation | Benzoates | Drug Administration Schedule | International Cooperation | Ticlopidine | Myocardial Infarction | Platelet Aggregation Inhibitors | Santé publique et épidémiologie | Original | Dipyridamole/adverse effects/therapeutic use | Angiotensin-Converting Enzyme Inhibitors/therapeutic use | Recurrence/prevention & control | Benzoates/therapeutic use | Brain Ischemia/epidemiology/prevention & control | MEDICIN OCH HÄLSOVETENSKAP | Platelet Aggregation Inhibitors/administration & dosage/adverse | Combination | MEDICAL AND HEALTH SCIENCES | Aspirin/administration & dosage/adverse effects | Myocardial Infarction/epidemiology | Factor Analysis | Benzimidazoles/therapeutic use | Drug Therapy | Ticlopidine/adverse effects/analogs & derivatives/therapeutic use | effects/therapeutic use | Vascular Diseases/mortality | Hemorrhage/chemically induced | Stroke/drug therapy/epidemiology/prevention & control | Statistical | Kaplan-Meiers Estimate
Journal Article
The New England journal of medicine, ISSN 1533-4406, 2017, Volume 377, Issue 16, pp. 1513 - 1524
..., and such findings have prompted efforts to seek new therapeutic strategies. 10 – 15 Two new promising approaches have emerged to reduce the risk of bleeding among patients... 
MEDICINE, GENERAL & INTERNAL | PERCUTANEOUS CORONARY INTERVENTION | HEART-DISEASE | MYOCARDIAL-INFARCTION | ORAL ANTICOAGULATION | 2011 ACCF/AHA/SCAI GUIDELINE | AMERICAN-COLLEGE | ASSOCIATION TASK-FORCE | TRIPLE THERAPY | ANTIPLATELET THERAPY | CONSENSUS DOCUMENT | Dabigatran - adverse effects | Ticlopidine - therapeutic use | Humans | Middle Aged | Warfarin - adverse effects | Male | Risk | Dabigatran - therapeutic use | Incidence | Warfarin - therapeutic use | Purinergic P2Y Receptor Antagonists - adverse effects | Drug Therapy, Combination - adverse effects | Adenosine - adverse effects | Adenosine - therapeutic use | Female | Aspirin - therapeutic use | Platelet Aggregation Inhibitors - therapeutic use | Ticagrelor | Purinergic P2Y Receptor Antagonists - therapeutic use | Hemorrhage - epidemiology | Atrial Fibrillation - drug therapy | Atrial Fibrillation - therapy | Anticoagulants - therapeutic use | Anticoagulants - adverse effects | Ticlopidine - analogs & derivatives | Adenosine - analogs & derivatives | Clopidogrel | Aged | Hemorrhage - chemically induced | Percutaneous Coronary Intervention | Warfarin | Atrial fibrillation | Dosage and administration | Research | Thromboembolism | Hemorrhage | Health aspects | Myocardial infarction | Cerebral infarction | Cardiac arrhythmia | Anticoagulants | Aspirin | Stroke | Embolisms | Preventive medicine | Thrombosis | Bleeding | Embolism | Fibrillation | Cardiology | Drug therapy | Drug dosages | Geriatrics
Journal Article
The American journal of medicine, ISSN 0002-9343, 2014, Volume 127, Issue 11, pp. 1075 - 1082.e1
Journal Article
Cochrane Database of Systematic Reviews, ISSN 1469-493X, 12/2016, Volume 2016, Issue 12, p. CD008500
Background Venous thromboembolism (VTE) often complicates the clinical course of cancer. The risk is further increased by chemotherapy, but the trade‐off... 
Prevention: physical approaches | Medical prophylaxis | Physical methods of prophylaxis | Hemorrhage | Neoplasms | Prevention | Antithrombins | Venous Thromboembolism | Child health | Prevention: medical approaches | Heart & circulation | Thromboembolism | Anticoagulants | Warfarin | Mechanical prophylaxis | Antineoplastic Agents | Deep vein thrombosis | Heparin, Low‐Molecular‐Weight | Ambulatory Care | Randomized Controlled Trials as Topic | Vitamin K Antagonists | Pulmonary Embolism (PE) | Deep vein thrombosis (DVT) related | Pulmonary Embolism | Heparin | Medicine General & Introductory Medical Sciences | Hemorrhage [chemically induced] | Pulmonary Embolism [etiology; prevention & control] Randomized Controlled Trials as Topic | LOW-DOSE WARFARIN | Humans | Anticoagulants [adverse effects; therapeutic use] | RANDOMIZED-TRIAL | Antithrombins [therapeutic use] | Heparin [adverse effects; therapeutic use] | FACTOR-BEARING MICROPARTICLES | Heparin, Low-Molecular-Weight [adverse effects; therapeutic use] | Neoplasms [complications; drug therapy] | BLEEDING COMPLICATIONS | CELL LUNG-CANCER | MEDICINE, GENERAL & INTERNAL | PHASE-II TRIAL | Venous Thromboembolism [etiology; prevention & control] Warfarin [adverse effects; therapeutic use] | MOLECULAR-WEIGHT HEPARIN | METASTATIC BREAST-CANCER | Adult | Antineoplastic Agents [adverse effects] | PLACEBO-CONTROLLED TRIAL | Child | DEEP-VEIN-THROMBOSIS | Pulmonary Embolism - prevention & control | Antithrombins - therapeutic use | Heparin, Low-Molecular-Weight - adverse effects | Warfarin - adverse effects | Anticoagulants - therapeutic use | Heparin - therapeutic use | Anticoagulants - adverse effects | Heparin - adverse effects | Heparin, Low-Molecular-Weight - therapeutic use | Neoplasms - drug therapy | Venous Thromboembolism - etiology | Warfarin - therapeutic use | Neoplasms - complications | Venous Thromboembolism - prevention & control | Antineoplastic Agents - adverse effects | Pulmonary Embolism - etiology | Hemorrhage - chemically induced
Journal Article